Jim Simons’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,296,984
| Closed | -$27.8M | – | 3273 |
|
|
2026
Q1 | $27.8M | Sell |
1,296,984
-8,100
| -0.6% | -$114K | 0.04% | 524 |
|
|
2025
Q4 | $12.2M | Buy |
1,305,084
+399,608
| +44% | +$3.34M | 0.02% | 826 |
|
|
2025
Q3 | $6.38M | Sell |
905,476
-95,064
| -10% | -$654K | 0.01% | 1349 |
|
|
2025
Q2 | $6.5M | Buy |
1,000,540
+652,100
| +187% | +$4.49M | 0.01% | 1348 |
|
|
2025
Q1 | $2.76M | Buy |
348,440
+104,700
| +43% | +$1.13M | ﹤0.01% | 1793 |
|
|
2024
Q4 | $3.09M | Buy |
243,740
+148,900
| +157% | +$2.07M | ﹤0.01% | 1755 |
|
|
2024
Q3 | $1.32M | Buy |
94,840
+22,700
| +31% | +$324K | ﹤0.01% | 2282 |
|
|
2024
Q2 | $994K | Buy |
+72,140
| New | +$1.06M | ﹤0.01% | 2326 |
|
|
2023
Q3 | – | Sell |
-139,164
| Closed | -$1.66M | – | 3732 |
|
|
2023
Q2 | $1.66M | Sell |
139,164
-239,936
| -63% | -$3.13M | ﹤0.01% | 2119 |
|
|
2023
Q1 | $5.07M | Buy |
379,100
+231,674
| +157% | +$4.53M | 0.01% | 1468 |
|
|
2022
Q4 | $3.17M | Buy |
147,426
+49,526
| +51% | +$1.02M | ﹤0.01% | 1780 |
|
|
2022
Q3 | $1.96M | Sell |
97,900
-18,730
| -16% | -$398K | ﹤0.01% | 2023 |
|
|
2022
Q2 | $2.09M | Buy |
+116,630
| New | +$1.2M | ﹤0.01% | 2152 |
|
Other funds holding DAWN
Jim Simons's DAWN Position: Q2 2026 in Review
Jim Simons sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 1,296,984 shares — an estimated $27.8M sold.
Jim Simons first reported a position in DAWN in Q2 2022 and held it in 13 quarters. The position peaked at $27.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- Jim Simons reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Jim Simons sold 1,296,984 Day One Biopharmaceuticals shares in Q2 2026, an estimated $27.8M.
- Jim Simons first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 13 quarters.
- Jim Simons's Day One Biopharmaceuticals position peaked at $27.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.